Topic Listing for CARDIUM THERAPEUTICS INC

A410 Notification Stockholders Regarding Right Dissent A420prerequisites Demand Payment Shares
A430 Dissenters Notice Delivery Stockholders Entitled Assert Rights A440demand Payment Deposit Certificates Retention Rights Stockholder
A450uncertificated Shares Authority Restrict Transfer After Demand Payment A460 Payment Shares General Requirements
A470payment Shares Acquired After Date Dissenters Notice A480dissenters Estimate Fair Value Notification Subject Corporation Demand
A490legal Proceeding Determine Fair Value Duties Subject Corporation A500legal Proceeding Determine Fair Value Assessment Costs Fees
Absence Undisclosed Liabilities Accepted Nyse Alternext
Accounting Debt Proceed Allocations Accounting Treatment
Accounts Receivable Accredited Investor Receipt Information
Accrued Liabilities Achieving Maintaining Normal Body Temperature
Acquisition Act
Action Respect Securities Other Corporations Action Written Consent
Additional Agreements Covenants Additional Product Candidate Heart Attack-corgentin Ad5igf-i
Additional Product Candidate Peripheral Vascular Disease-genvascor Ad5enos Additional Targeted Tissue Cooling
Address Notice Adjournment
Adjournment Stockholder Meetings Adjournments
Adjustment Adjustments
Adjustments Changes Capitalization Adjustments Shares Subject Plan
Administration Advance Notice Stockholder Business
Advancement Expenses Age
Aggregated Option Exercises End Values Agreement
Agreement Merger Plan Reorganization Allocation Purchase Price
Amended Restated Certificate Incorporation Cardium Therapeutics Inc Amendment
Amendment Certificate Incorporation Change Name Amendment Employment Agreement
Amendment Exclusive License Agreement Between Yale University Cardium Amendment Lease Agreement
Amendment License Agreement Amendment Placement Agent Agreement
Amendment Promissory Notes Amendment Release Collateral
Amendment Termination Amendment Waiver
Amendments Amendments Articles Incorporation Bylaws Change
Amendments Bylaws American Heart Attack Association Reported Patients United States
Angiogenesis Gene Therapy Congestive Heart Failure Angiogenic Gene Therapy Heart Disease
Annual Meeting Annual Meeting Proxy Card
Annual Meetings Annual Report
Anti-takeover Laws Apportionment
Appraisal Rights Procedures Approval 2005 Equity Incentive Plan
Approval Increase Authorized Capital Stock 60000000 50000000 Common Approval Stockholders Amendment Effective Date
Approve Amendment Change Required Vote Proposals Previously Approved Aries Ventures Inc
Asset Purchase Agreement Assets Contracts
Assignment Assumption Assignment Form
Attendance Annual Meetings Attorneys Fees
Audit Committee Report Audit Fees
Audit-related Fees Authority Board
Authority Violation Authorized Shares
Authorized Signatures Sign Here Completed Instructions Executed Available Information
Award Agreement Award Arbitration Shall Sufficient Given Accordance Provisions Agreement
Award Price Consideration Withholding Aware Study
Balance Sheet 2005 Basis Presentation
Because Cannot Predict Whether Obtain Regulatory Approval Commercialize Before Sale Shares Warrants Cardium Therapeutics Inc Questionnaire
Beneficial Ownership Reporting Compliance Benefits Inducing Hypothermia Aneurysm Surgery
Benefits Received Plan Binding Agreement
Biologics Stem Cells Cardiovascular Disease Other Indications Biologics Stem Cells Regenerative Medicine
Board Committees Board Directors
Board Meetings Board Members
Borrower Borrowers
Bridge Loans Bulk Sales Legal Requirements Applicable Transaction 430 Foreign
Business Prospects Difficult Evaluate Because Development Stage Developing Business Prospects Difficult Evaluate Because New
Business Prospects Difficult Evaluate Because New Developing Complex Business Strategy
Calculations Captions
Carco Cardiac Arrest
Cardiothoracic Surgery Cardiovascular-directed Growth Factors-generx
Cardium Cardium Adopts Stockholder Rights Plan
Cardium Announces 215 Equity Financing Cardium Announces Completion Patient Recruitment
Cardium Announces Registered Direct Offering Cardium Biologics Inc
Cardium Completes Credit Facility Cardium Completes Financing
Cardium Completes Registered Direct Investment Cardium Completes Registered Direct Offering
Cardium Development Stage Formed 2003 Incurred Losses Since Cardium Initiates Phase Aware Clinical Study
Cardium Initiates Phase Excellarate Clinical Study Diabetic Ulcers Cardium Regains Listing Compliance Nyse Amex
Cardium Therapeutics Cardium Therapeutics Generx Trademarks Inc
Cardium Therapeutics Inc Cardium Therapeutics Inc Delaware Corporation
Cardiums Clinical Development Program Cardiums Orthobiologics Research
Cardiums Proxy Statement Annual Report Stockholders Available On-line Carisa Data Least Square Means Other Study Arithmetic
Cash Equivalents Cash Equivalents Short-term Investments
Certain Federal Income Tax Consequences Proposed Reincorporation Certain Recent Events
Certain Relationships Related Transactions Certificate Merger Domestic Corporations
Certificate Officer Certificates
Certificates Stock Chairman Board Chief Executive Officer President Treasurer
Chairman Secretary Meetings Change Business Management Board Members Assets Liabilities Location
Change Capital Structure Resulting Proposed Reincorporation Change Control
Change Vote After Submit Proxy Changes Certifying Accountant
Changes Control Registrant Changes Indebtedness
Changes Internal Control Over Financial Reporting Changes Reforms Health Care System Reimbursement Policies Adversely
Changes Registrants Certifying Accountant Charter Bylaws
Charter Capital Structure Check Applicable Box
Chief Business Officer General Counsel Executive Vice President Chief Financial Officer
Chief Scientific Officer Choose Voting Methods Outlined Below Vote Proxy
Christopher Reinhard Age Class
Click Here Appendix Closing
Closings Code Ethics
Collaborative Licensing Arrangements Collateral Agent
Commencement Letter Commentary
Commercial Sale Europe Certification Commitments Contingencies
Committees Committees Board Directors
Common Shares Reserved Issuance Common Stock
Common Stock Private Placement Common Stock Purchase Warrants
Comparative Anti-anginal Therapeutic Approaches Compared 2005
Compared 2006 Compared 2007
Compared 2008 Comparison Cumulative Total Return
Compensation Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Directors
Compensation Discussion Analysis Competition
Completion Acquisition Disposition Assets Compliance Applicable Laws
Concentration Credit Risk Condensed Consolidated Statements Cash Flows
Condensed Consolidated Statements Stockholders Deficiency Conditions Closing
Conditions Issuance Shares Conditions Precedent Closing
Conduct Business Conduct Meeting
Conduct Prior Closing Conference Matrix Wound Healing Clinical Development
Confidential Information Confidential Information Implied Warranty
Confidential Purchaser Questionnaire Conflicts
Conflicts Required Consents Consideration
Consideration Up-front Payment Milestones Royalties Construction
Contractual Obligations Controls Procedures
Conversion Certificates Plans Coolblue Convenient Surface System
Copy Corgentin
Corgentin Pre-clinical Development Corgentin Therapeutic Approach Heart Attack
Coronary Artery Disease Chronic Angina Corporate Seal
Corporation Used Whenever Authorized Board Directors Committee Thereof Counterparts
Covenants Creation Direct Financial Obligation Off-balance Sheet Arrangement
Critical Accounting Policies Estimates Current Approaches Angina Treatment
Current Treatment Approaches Chronic Wounds Current Treatments Heart Disease Angina
Currently Participating Matrix Clinical Sites Customers Suppliers
Debt Limits Ability Fund General Corporate Requirements Flexibility Deferrals
Deferred Financing Costs Definitions
Delaware Corporation Delegation Authority
Delisting Nyse Amex Adversely Affect Price Common Stock Deliver Bone Growth Factors
Dennis Mulroy Age Departure Directors Principal Officers Election Appointment
Derivative Liabilities Description Property
Development Stage Formed 2003 Incurred Losses Since Inception Development Stage Incurred Losses Since Inception 2003 Expect
Differences Franchise Taxes Difficult Acquire Due Anti-takeover Provisions Charter Stockholder Rights
Director Director Chief Business Officer General Counsel Executive Vice
Director Compensation Directors
Directors Executive Officers Corporate Governance Directors Officers Surviving Corporation
Disclaimers Indemnification Disclosure Controls Procedures
Disclosure Information Disclosure Schedules
Dissolution Liquidation Distribution Agreement Coolblue Rapid Blue Systems
Dividend Rights Repurchase Shares Dividends
Documents Incorporated Reference Duration Proxies
Early Exercise Earnings Per Common Share
Earnout Effect Amendment Termination
Effect Boards Decisions Effect Ratification
Effected Meeting Effective Date New Merger
Election Class Directors Election Directors
Election Staggered Terms Office Election Term Office
Electronic Communications Eligibility
Empire Empire Asset Management
Employees Employees Consultants
Employment Agreement Employment Agreements
Employment Service Rights Endorsed Include Contractual Liability Coverage Licensees Indemnification 131
Endovascular Temperature Control-the Innercool Celsius Control System Rapidblue Endovascular Temperature Modulation Therapy Heart Attack
Entire Agreement Entry Material Definitive Agreement
Escrow Agent Escrow Deposit Agreement
Escrow Instructions Estimates
Even Approved Marketing Technologies Product Candidates Relatively Novel Exact Name Registrant Specified Charter
Excellarate New Formulation Advancements Exchange Act
Exchange Programs Modification Awards Exchange Stock
Execution Executive Compensation
Executive Officers Executive Overview
Executive Vice President Chief Medical Officer Exercise Following Termination Continuous Service
Exercise Outstanding Warrants Significantly Dilute Ownership Interest Existing Exercise Procedures
Exercise Purchase Price Exhibits
Expected Announced Late 2009 Expense Reimbursement
Experience Delays Clinical Trials Adversely Affect Business Financial Experience Delays Generx Other Clinical Trials Adversely Affect
Explanatory Extent Enter Markets Outside United States Business Subject
Face Intense Competition Cope Rapid Technological Change Adversely Face Intense Increasing Competition Cope Rapid Technological Change
Face Risk Product Liability Claims Adversely Affect Business Facilities Located Near Seismic Zones Earthquake Other Natural
Facsimile Signatures Fair Value Financial Instruments
Fdic Insured Limits Fiduciary Duties Directors
Fifth Final Adjudication
Final Closing Financial Report
Financial Results 2009 Outlook Financial Statements
Financial Statements Exhibits Findings Agent Studies
Findings Generx Now Phase Heart Disease Fixing Date Determination Stockholders Record
Following Chart Summarizes Certain Attributes Above Described Product Following Heart Attack
Following Meeting Fda Form Escrow Release Notice
Form Lock-up Agreement Form Opinion Counsel
Form Opinion Parents Counsel Form Records
Form Representation Letter Parent Representations Warranties Director Form Representation Letter Parent Representations Warranties Zucker
Form Representation Letter Representations Warranties Directors Former Name
Former Name Address Changed Since Last Report Forward-looking Statements
Further Assurances Future Acquisitions Disrupt Business Harm Financial Condition
Future Sales Results Commitment Gam Technology
Gene Activated Matrix Gam Technology Gene Activated Matrix Gam Trademarks Tissue Repair
Gene Activated Matrix Technology Orthobiologics Initiative Gene Activated Matrix Technology Platform
General Considerations Description Proposed Amendment General Corporation Law
General Powers General Release
General Rule Generally
Generx Generx Advances Phase Following Meetings Fda
Generx Clinical Data Meta-analysis Phase Protocol Generx Clinical Development Strategy
Generx Clinical Studies Generx Excellarate Late-stage Development Activities
Genvascor Pre-clinical Development Gerald Lewis Age
Governing Law Government Regulation
Grants Plan-based Awards Growth Factor Gene Portfolio
Guidance Industry Cmc Human Gene Therapy Inds 2004 Hazardous Biological Materials Business Claims Relating Improper Handling
Heart Attack Acute Myocardial Infarction Ami Heart Disease Stroke Statistics-2005 Update
Historical Background Holders
However Http Wwwprnewswirecom Mnr Cardiumtherapeutics 25164
Ictus Studies Impairment Long-lived Assets
Incentive Stock Options Incidence Chronic Wounds
Incidence Heart Disease Angina Income Taxes
Indemnification Indemnification Directors Officers
Indemnification Employees Agents Corporation Indemnification Officers Directors
Indemnitee Independence
Independent Registered Public Accounting Firms Consent Index
Information Provided Participants Initial Offering Period
Innercool Innercool Become Only Comprehensive Temperature Modulation Provider
Innercool Launches Coolblue Patient Temperature Modulation System Innercool Licenses New Therapeutic Potential Stroke Patients
Innercool Therapies Innercool Therapies Acquisition
Innercool Therapies Inc Innercool Therapies Transaction Subsequent Product Development
Innercools Endovascular Temperature Modulation Systems Innercools Rapidblue Coolblue Temperature Modulation Systems
Innercools Surface Endovascular Temperature Modulation Systems Innovative Advanced Care Dna-based Therapy
Institutional Investor Insurance
Intangible Assets Intellectual Property
Interested Director Transactions Interested Directors Quorum
Interested Party Transactions Intracoronary Infusion
Introduction Introduction Pro Forma Condensed Consolidated Financial Information
Inventories Investment Representations Warranties
Issuance Notes Warrants Issuance Promissory Notes
Landmark Gene Therapy Study Non-healing Diabetic Ulcers Potential Lapsed Awards
Lead Investor Warrants Lease Commitments
Legal Description Project Legal Matters
Legal Proceedings Lessons Learned Meta-analysis Agent-3 Agent-4
Letter Agreement Letter Credit
Liability Directors Officers Licensee Gives Notice Pursuant Shall Deemed Material Breach
Limitation Award Amounts Rule 701 Limitations Repurchase Rights
Limited Transferability Awards Liquidity
Liquidity Capital Resources Liquidity Going Concern
List Stockholders Entitled Vote Loan Security Agreement
Localized Cooling Prostate Surgery-urocool Long-lived Assets
Long-term Debt Loss Per Common Share
Lost Stolen Destroyed Certificates Management Fee
Managements Annual Report Internal Control Over Financial Reporting Manufacturing Strategy
Market Information Market Opportunity Orthobiologics
Marketing Allowance Marketing Sales
Material Adverse Effect Material Contracts
Matrix Study Completion Plans Maximum Amount
Measurement Memorandum
Men Heart Disease Merger Agreement
Method Reincorporation Michael Magers Age
Minimum Amount Miscellaneous
Miscellaneous Provisions Modified Boma Standard
Myocardial Reperfusion Injury Name Contact Information
Name Person Filing Proxy Statement Other Registrant Nature Rights
Need Substantial Additional Capital Develop Products Future Operations Need Substantial Additional Funding Develop Products Future Operations
Negative Public Opinion Increased Regulatory Scrutiny Gene Therapy Never Paid Cash Dividends Capital Stock Not Anticipate
New Clinical Heart Attack Study Underway New Data Suggest Potential Benefits Targeted Tissue Cooling
New Excellarate Product Formulations Expanded Applications New York University Research License Agreement
Newly Created Directorships Vacancies Nominees
Non-exclusivity Rights Nonexclusivity Plan
Nonqualified Defined Contribution Other Deferred Compensation Plans Nontransferability
Not Able Maintain Adequate Patent Protection Product Candidates Not Able Maintain Adequate Patent Protection Products Product
Not Adequate Protection Unpatented Proprietary Information Adversely Affect Not Comply Applicable Regulatory Requirements Manufacture Distribution Product
Not Comply Applicable Regulatory Requirements Manufacture Distribution Products Not Successfully Establish Maintain Collaborative Licensing Arrangements Adversely
Notes Financial Statements Notes Payable
Notice Annual Meeting Stockholders Notice Exercise
Notice Meetings Notice Stockholder Nominees
Notices Notices Record Date Etc Case
Number Number Election Term Directors
Number Qualifications Obligations Stockholders
Observational Safety Efficacy Insights Off-balance Sheet Arrangements
Offering Price Officers
Operations Option Activity
Option Exercises Stock Vested Option Extend
Optional Term Extension Payments Options
Organization Orthobiologics Initiative
Other Events Other Fees
Other Matters Other Stock Cash Awards
Outstanding Equity Awards End Overview
Ownership Shares Parent Asset Dispositions
Parent Assets Contracts Parent Changes Indebtedness
Parent Disclosure Schedules Parent Employees
Parent Interested Party Transactions Parent Obligations Stockholders
Parent Patents Trademarks Etc Part
Part Other Information Participation Meetings Conference Telephone
Parties Interest Patent Proceedings
Patent Trademarks Etc Patented Technology Other Intangible Assets
Patents Patent Proceedings Patents Treatment Heart Disease
Patient Temperature Modulation Patient Temperature Modulation Systems
Pays Proxy Solicitation Pension Benefits
Performance Goals Performance Graph
Performance Stock Units Phase Aware Study
Phase Excellarate Study Published Wound Repair Regeneration Placebo Also Observed Time Onset Angina 10e9 P0029
Placement Agency Agreement Placement Agent Party
Placement Agent Warrant Plan Distribution
Plans Commercial Development Excellagen Positive Effects Hypothermia Following Heart Attack
Post Closing Investor Post-operative Incontinence Erectile Dysfunction
Powers Duties Pre-approval Policies Procedures
Preferred Stock Preserve Cardiac Function Following Heart Attack
President President Chief Operating Officer Innercool
President Chief Operating Officer Innercool Therapies Inc Press Investor Contact
Press Investor Contacts Price Common Stock Expected Volatile Investment Decline Substantially
Price Common Stock Expected Volatile Investment Decline Value Principal Accounting Fees Services
Principal Features Plan Principal Reasons Proposed Reincorporation
Principal Terms Merger Principles Consolidation
Prior Plans Pro Forma Adjustments
Pro Forma Financial Information Procedure
Procedure Exercise Rights Shareholder Procedures Indemnification
Proceeding Product Candidates Not Effectively Protected Valid Issued Patents
Product Candidates Not Successfully Complete Clinical Trial Process Product Candidates Unacceptable Side Effects Delay Prevent Approval
Product Development Efforts Diligence Product Portfolio Acquired Schering
Promissory Warrant Purchase Agreement Properties
Property Equipment Proposal
Proposals-the Board Directors Recommends Vote Each Nominees Listed Proposed Adopted
Prostate Cancer Prostate Surgery Other Surgical Procedures
Provide Such Policy Primary Not Excess Contributory Regard Provided However
Proxies Voting Proxy Properly Executed Voted Specified Choice Then Election
Proxy Solicited Behalf Board Directors Proxy Statement
Purchase Entirely Own Account Purchase Form
Purchase Price Purchase Sale
Purchase Technology Schering Purchase Technology Schering Group Germany
Purchaser Purpose Effect Proposed Amendment
Purposes Plan Quantitative Qualitative Disclosures Market Risk
Quarterly Consolidated Financial Data-unaudited Quorum
Quorum Required Vote Quorum Vote Required
Radical Prostatectomy Rapid Early Cooling Heart Attack Preclinical Study Results
Rapidblue Endovascular System Rapidblue High-performance Endovascular System
Rata Ratification Selection Auditors
Ratification Selection Independent Registered Public Accounting Firm Real Property Leases
Recent Accounting Pronouncement Recent Accounting Pronouncements
Recent Developments 2009 Outlook Recent Sales Unregistered Securities
Recently Adopted Accounting Pronouncements Recently Issued Adopted Accounting Pronouncements
Recitals Reclassification
Record Date Registered Direct Offering
Registered Holders Regular Meetings
Regulation Regulations
Reliance Books Reports Records Rely Parties Manufacture Product Candidates Guarantee Obtain Sufficient
Rely Party Clinical Research Organizations Manage Trials Business Remainder Page Intentionally Left Blank
Removal Removal Directors
Removals Removed Cause Stockholder Approval
Report Independent Registered Public Accounting Firm Report Matrix Phase Clinical Trial
Representation Letter Representations Warranties
Representations Warranties Borrower Representations Warranties Buyer
Representations Warranties Buyer Parent Representations Warranties Investors
Representations Warranties Lenders Representations Warranties Seller
Repurchases Research Development
Reservation Shares Resignations
Restricted Cash Restricted Securities
Restricted Stock Restrictions Shares
Restrictions Transfer Restrictions Transfer Sale
Results Operations Results Recent Developments
Revenue Recognition Reverse Merger
Reverse Merger Transaction Revised Business Strategies Operating Units
Right Advancement Expenses Right Exercise
Right Indemnification Right Indemnitee Bring Suit
Right Intellectual Property Intend License Parties Terminated Adversely Right Refusal
Rights Dissenting Stockholders Risk Factors
Risks Risks Related Intellectual Property Potential Litigation
Royal Philips Electronics Rule 13a-14 15d-14
Rules Regulations Sale Innercool Therapies Business
Sale Innercool Therapies Royal Philips Electronics Sale Promissory Warrant
Santa Monica Boulevard Suite 1250 Los Angeles California Schedule
Schedule Employee Benefit Plans Schering Agreement
Schering Transaction Seal
Secretary Secured Promissory
Securities Act Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Act 1934 Securities Purchase Agreement
Securities Registered Exchange Act Security Agreement
See Notes Condensed Financial Statements See Notes Pro Forma Condensed Consolidated Financial Statements
See Notes Pro Forma Condensed Financial Statements Selling Commissions
Selling Stockholder Questionnaire Senior Subordinated Secured Promissory Amendment
Separate Programs Separation Agreement General Release Claims
Seventh Severability
Shall Construed Accordance Governed Laws State New York Shares Begin Trading 2007 Symbol Cxm
Short Term Debt Short-term Debt
Shows Positive Effects Men Women Heart Disease Signature Page
Signature Page Follows Signature Page Warrant Purchase Agreement
Signature Pages Follow Signatures
Signatures Follow Separate Page Signatures Following Page
Sixth Sold Assets Business Innercool Therapies Inc 2009 Face
Special Forward-looking Statements Special Meetings
Special Provisions Relating Certain Types Awards Statement Operations 2005
Statements Operations Stem Cells Improve Cardiac Function After Heart Attack
Stock Stock Appreciation Rights Sars
Stock Holdings Certain Owners Management Stock List
Stock Performance Shown Above Not Indicative Future Stock Subject Plan
Stock-based Compensation Stockholder Approval
Stockholder Communications Directors Stockholder Proposals
Stockholder Rights Plan Stockholders
Stockholders Rights Examine Books Records Strategic Business Transactions
Strategic Goals Stroke
Study Publication Wound Repair Regeneration Subject Costly Claims Unsuccessful Resolving Conflicts Regarding Patent
Sublicensing Assignments Cardium Submission Matters Vote Security Holders
Subscription Agreements Subsections 1350 Chapter Title United States Code
Subsequent Event Subsequent Events
Substantial Risk Substitution Assumption Benefits
Such Registration Issuance Exchange Replacement Case Office Agent Summary Compensation Table
Summary Strategic Acquisitions Supplemental Financial Data
Surface-based Temperature Control-coolblue Surmodics License Agreement
Survival Representations Warranties Systems New York Neurological Symposium
Table Contents Tax Consequences Relating Stock Options
Tax Fees Taxes
Technologies Product Candidates Unacceptable Side Effects Delay Prevent Technologies Product Candidates Unproven They Fail Gain Market
Technology Science Generx Technology Transfer Cardium
Telephonic Meetings Permitted Temperature Modulation Systems
Temperature Modulation Therapy Ischemic Injury Term
Term Amendment Waiver Termination Term Award
Term Expiration Term Termination Survival
Termination Termination Amendment Waiver Expenses
Termination Date Terms Conditions
Terms Privacy Policy Please Visit Wwwcardiumthxcom Therapeutic Hypothermia Stroke-the Ictus-l Study
Time Periods Times Carry Out Such Terms Take Action Reasonably
Tissue Repair Tissue Repair Acquisition
Tissue Repair Product Candidate-excellarate Tissue Repair Transaction
Title Properties Encumbrances Title Sufficiency Condition Assets
Trademarks Tissue Repair Transfer Consent Amendment Assumption License Agreement
Transfer Conveyance Assets Assumption Liabilities Transfer Set Forth Warrant
Transfer Taxes Prorations Transferability Shares
Transfers Stock Treasurer
Treatment Acute Ischemic Conditions Using Patient Temperature Modulation Treatment Coronary Heart Disease
Tyler Dylan Phd Age Types Awards
Unable Attract Retain Key Personnel Advisors Adversely Affect Unable Create Maintain Sales Marketing Distribution Capabilities Enter
Undertaking Undisclosed Liabilities
University California License Agreement University Michigan License Agreement
Unregistered Sales Equity Securities Unregistered Sales Equity Securities Proceeds
Vacancies Venous Ulcers Other Dermal Wounds
Venous Ulcers Other Topical Wounds Venue
Vice President Vitro
Vivo Vote
Vote Person Annual Meeting Instead Voting Proxy Vote Proxy
Vote Proxy Internet Telephone Facsimile Not Need Mail Votes Counted
Votes Needed Hold Annual Meeting Votes Required Approve Each Proposal
Voting Proxies Waiver
Waiver Notice Meetings Stockholders Directors Committees Waivers
Warrant Warrant Purchase Agreement
Warrant Purchase Shares Common Stock Warrants
What Approval Proposal Means What Proxy
Withholding Witness Whereof
Witnesseth Women Heart Disease
Work Letter Wwwinnercoolcom
Yale Shall Right Terminate Agreement Written Notice Licensee Yale University License Agreement
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki